Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
Q8WXU2
UPID:
DAAF4_HUMAN
Alternative names:
Dyslexia susceptibility 1 candidate gene 1 protein
Alternative UPACC:
Q8WXU2; Q6P5Y9; Q8N1S6
Background:
Dynein axonemal assembly factor 4, also known as Dyslexia susceptibility 1 candidate gene 1 protein, plays a crucial role in ciliary motility, essential for respiratory health and embryonic development. It is pivotal in neuronal migration during the cerebral neocortex development and may influence estrogen receptors' stability, impacting neuronal differentiation and survival.
Therapeutic significance:
The protein's association with Dyslexia 1 and Primary Ciliary Dyskinesia, including Kartagener syndrome, underscores its therapeutic potential. Understanding the role of Dynein axonemal assembly factor 4 could open doors to potential therapeutic strategies for these complex disorders.